ARS Pharmaceuticals, Inc. (SPRY) vs Tectonic Therapeutic, Inc. (TECX)
A side-by-side comparison of ARS Pharmaceuticals, Inc. and Tectonic Therapeutic, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SPRY
ARS Pharmaceuticals, Inc.
$4.28HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
TECX
Tectonic Therapeutic, Inc.
$23.16HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Total return — SPRY vs TECX
growth of $100 · dividends reinvested · last 6ySPRY -82.8% (-25.5%/yr)TECX -85.6% (-27.6%/yr)SPRY compounded faster over this window
SPRY TECX
SPRY vs TECX: by the numbers
- •TECX is the larger company ($437M vs $425M market cap).
- •Both run net losses; TECX's is the smaller (0.00% vs -184.24% net margin).
Metrics side by side
Valuation
| Metric | SPRY | TECX |
|---|---|---|
| P/S ratio | 3.64 | N/A |
| P/B ratio | 33.98 | 1.95 |
Profitability
| Metric | SPRY | TECX |
|---|---|---|
| Gross margin | 73.89% | 0.00% |
| Operating margin | -212.92% | 0.00% |
| Net margin | -184.24% | 0.00% |
| ROE | -1721.80% | -38.32% |
| ROIC | -114.65% | -41.88% |
Growth (annualized)
| Metric | SPRY | TECX |
|---|---|---|
| Revenue CAGR (5Y) | 36.43% | N/A |
| Total return CAGR (5Y) | -16.35% | -18.45% |
Frequently asked
- How have SPRY and TECX total returns compared?
- Over the past 5 years, SPRY delivered -16.35% and TECX delivered -18.45% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ARS Pharmaceuticals ROETectonic Therapeutic ROEARS Pharmaceuticals operating marginTectonic Therapeutic operating marginARS Pharmaceuticals revenue growthTectonic Therapeutic revenue growthARS Pharmaceuticals free cash flowTectonic Therapeutic free cash flow
ARS Pharmaceuticals & Tectonic Therapeutic appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.